The third quarter of 2026 was a transformational period for Ensysce. In August, the Company completed the acquisition of
"Ensysce is a fundamentally different company today than it was at the start of the year," said Dr.
CY200 and Complex Regional Pain Syndrome (CRPS) Program Update
CY200 is a psilocybin-predominant botanical extract being developed for CRPS. Its development follows an observational pilot study of psilocybin in patients with CRPS and other chronic pain conditions that was funded by
In
On
"Our priority since the acquisition has been to advance CY200 efficiently, and submitting the
The Company intends to apply proceeds from recent private placement financings primarily to advance CY200 through this study and to prepare for registrational development. Also in
TAAP™ and MPAR® (Opioid Abuse Deterrent and Overdose Protection Programs) Update
Trypsin-Activated Abuse Protection (TAAP™) PF614 is designed to be a next-generation extended-release oxycodone with built-in abuse protection. PF614 remains inactive until it is swallowed and exposed to trypsin in the small intestine, where it "switches on" to release oxycodone in a controlled manner, designed to reduce the potential for abuse through non-oral routes such as injection and snorting. Development of PF614 continues in the pivotal PF614-301 Phase 3 trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating PF614 for the treatment of moderate to severe pain following abdominoplasty.
PF614-MPAR, which combines the active analgesic, TAAP™ PF614, with the Company's MPAR® (Multi-Pill Abuse Resistance) technology and has received FDA Breakthrough Therapy designation, is designed to deliver effective opioid analgesia with built-in protection against oral overdose. In
Q3 2026 Financial Results
Cash - Cash and cash equivalents were
Federal Grants - Funding under federal grants totaled
Research & Development Expenses - R&D expenses were
General & Administrative Expenses - G&A expenses were
Other Income (Expense) - Total other income (expense) was income of
Net Income (Loss) - Net loss attributable to common stockholders for the third quarter of 2026 was
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotechnology company developing novel neuroplastogenic therapies using psychedelics that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. The Company is also developing a new class of highly novel opioids for the treatment of severe pain while minimizing the risk of both drug abuse and overdose. For more information, please visit www.ensysce.com.
Definitions
CRPS: complex regional pain syndrome - a severe chronic pain disorder for which there is currently no approved therapy.
TAAP™: trypsin activated abuse protection - designed to protect against prescription drug abuse.
MPAR®: multi-pill abuse resistance - designed to protect against abuse and accidental overdose.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon management's estimates and forecasts and reflect the current views, assumptions, expectations and opinions of the Company as of the date hereof. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expected, including (i) possible Nasdaq delisting; (ii) failure to obtain stockholder approval for the conversion of the Series C non-voting convertible preferred stock into shares of common stock of the combined company; (iii) risks related to the combined company's ability to manage its operating expenses and its expenses associated with the acquisition; (iv) unexpected costs, charges or expenses resulting from the acquisition; (v) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition; (vi) the uncertainties associated with the combined company's product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement and completion of clinical trials, studies and evaluations (including in connection with the MHRA's request for additional information on the CY200 Phase 2a clinical trial application); (vii) risks related to the inability of the combined company to obtain sufficient additional capital, including the continuation of government funding, to continue to advance these or other product candidates; (viii) failure to achieve the clinical trial milestone for the milestone closing of the Series C private placement; (ix) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the acquisition, including with respect to future financial and operating results. These statements are also subject to risks and uncertainties described in Ensysce's most recent annual report on Form 10-K and quarterly report on Form 10-Q and in other filings that it makes with the U.S. Securities and Exchange Commission (the "SEC"), available at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
Ensysce Biosciences, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Federal grants | $ | 2,181,632 | $ | 493,104 | $ | 4,306,945 | $ | 3,184,314 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 3,175,848 | 2,954,909 | 8,994,480 | 6,763,866 | ||||||||||||
General and administrative | 1,594,722 | 1,279,290 | 4,040,022 | 3,879,569 | ||||||||||||
Acquired in-process research and development | 79,907,223 | - | 79,907,223 | - | ||||||||||||
Total operating expenses | 84,677,793 | 4,234,199 | 92,941,725 | 10,643,435 | ||||||||||||
Loss from operations | (82,496,161 | ) | (3,741,095 | ) | (88,634,780 | ) | (7,459,121 | ) | ||||||||
Total other income (expense), net | 382,578 | 11,967 | 393,907 | 50,903 | ||||||||||||
Net loss | $ | (82,113,583 | ) | $ | (3,729,128 | ) | $ | (88,240,873 | ) | $ | (7,408,218 | ) | ||||
Adjustments to net loss | (204,539 | ) | - | (204,373 | ) | 166 | ||||||||||
Net loss attributable to common stockholders | $ | (82,318,122 | ) | $ | (3,729,128 | ) | $ | (88,445,246 | ) | $ | (7,408,052 | ) | ||||
Net loss per share attributable to common stockholders, basic and diluted | $ | (4.52 | ) | $ | (1.29 | ) | $ | (6.95 | ) | $ | (3.42 | ) | ||||
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months Ended | ||||||||
| 2026 | 2025 | |||||||
Net cash used in operating activities | $ | (6,859,977 | ) | $ | (6,280,459 | ) | ||
Net cash provided by (used in) investing activities | 11,392,335 | (123,643 | ) | |||||
Net cash provided by financing activities | 21,065,072 | 4,575,243 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (236,991 | ) | - | |||||
Change in cash and cash equivalents | 25,360,439 | (1,828,859 | ) | |||||
Cash and cash equivalents at beginning of period | 4,310,354 | 3,502,077 | ||||||
Cash and cash equivalents at end of period | $ | 29,670,793 | $ | 1,673,218 | ||||
Condensed Consolidated Balance Sheets
(Unaudited)
| 2026 | 2025 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 29,670,793 | $ | 4,310,354 | ||||
Prepaid expenses and other current assets | 1,126,309 | 2,934,664 | ||||||
Total current assets | 30,797,102 | 7,245,018 | ||||||
Other assets | 156,279 | 207,461 | ||||||
Total assets | $ | 30,953,381 | $ | 7,452,479 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 2,033,669 | $ | 3,267,610 | ||||
Accrued expenses and other liabilities | 1,653,060 | 993,411 | ||||||
Notes payable and accrued interest | 154,874 | 306,708 | ||||||
Total current liabilities | 3,841,603 | 4,567,729 | ||||||
Long-term liabilities | - | - | ||||||
Total liabilities | 3,841,603 | 4,567,729 | ||||||
Stockholders' equity | 27,111,778 | 2,884,750 | ||||||
Total liabilities and stockholders' equity | $ | 30,953,381 | $ | 7,452,479 | ||||
SOURCE:
View the original press release on ACCESS Newswire